



**TERMINAL DISCLAIMER TO OBTAIN A DOUBLE
PATENTING
REJECTION OVER A "PRIOR" PATENT**

Docket No.: 4952.US.C1
(ABE1207P0240US)

Applicant(s):	Leonard Katz et al.	Confirmation No.: 609
Serial No.:	09/735,056	Filing Date: December 11, 2000
Group Art Unit:	1652	Examiner: William Moore
Invention: Method of Directing Biosynthesis of Specific Polyketides		

The owner*, Abbott Laboratories, of 100% (one hundred percent) interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term of prior patent No. 6,004,787 as the term of said prior patent is defined in 35 U.S.C. 154 and 173, and as the term of said prior patent is presently shortened by any terminal disclaimer. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of the term of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of the prior patent, "as the term of said prior patent is presently shortened by any terminal disclaimer," in the event that said prior patent later:

- expires for failure to pay a maintenance fee;
- is held unenforceable;
- is found invalid by a court of competent jurisdiction;
- is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321;
- has all claims canceled by a reexamination certificate;
- is reissued; or
- is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

Check either box 1 or 2, if appropriate.


1. For submission on behalf of a business/organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the business/organization.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

2. The undersigned is an attorney of record.*

Terminal Disclaimer fee under 37 CFR 1.20(d) is enclosed in the amount of: \$130.00 (large entity)
 \$65.00 (small entity)

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account Number 23-0785. A duplicate copy of this sheet is enclosed.


Diane Casuto, Reg. No. 40,943

June 20, 2005
Date

Abbott Laboratories
100 Abbott Park Road
Department 377/AP6A
Abbott Park, IL 60064-6008
(847)-938-3137

* Statement under 37 CFR 5.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this certification. See MPEP §324.

Page 1 of 2

U.S.S.N. 09/735,056

07/26/2005 HVUONG1 00000118 09735056

02 FC:1814

130.00 OP



CERTIFICATE OF MAILING

I hereby certify that this Terminal Disclaimer To Obviate A Double Patenting Rejection Over A "Prior" Patent, and any document referred to as being enclosed, is being deposited with the United States Postal Service with sufficient postage at First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on July 20, 2005.

Lydia Liepinaitis

Lydia Liepinaitis